Savara (SVRA) Income from Continuing Operations (2010 - 2026)
Savara (SVRA) reported Income from Continuing Operations of 37933000.0 for Q1 2026, down 42.4% year-over-year from 65851885.76 in Q1 2025, and down 17.72% quarter-over-quarter from 32224000.0 in Q4 2025.
Savara (SVRA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Income from Continuing Operations data on file, last reported at 37933000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 37933000.0, down 42.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 130383000.0 (down 27.52% YoY), and the FY2025 annual result was 119385000.0, down 23.42% from the prior year.
- Income from Continuing Operations declined to 37933000.0 in Q1 2026 per SVRA's latest filing, from 32224000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 8616000.0 in Q1 2022 and troughed at 37933000.0 in Q1 2026.
- A 5-year average of 20439529.41 and a median of 20346000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations climbed 21.72% in 2022, then sank 92.13% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 10261000.0 in 2022, then plunged by 57.01% to 16111000.0 in 2023, then sank by 81.62% to 29261000.0 in 2024, then declined by 10.13% to 32224000.0 in 2025, then retreated by 17.72% to 37933000.0 in 2026.
- Business Quant data shows SVRA's Income from Continuing Operations at 37933000.0 in Q1 2026, 32224000.0 in Q4 2025, and 29707000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -37.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.93 Mn |
| Dec 31, 2025 | -32.22 Mn |
| Sep 30, 2025 | -29.71 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.26 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | -22.12 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.11 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.51 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.26 Mn |
| Sep 30, 2022 | -10.38 Mn |
| Jun 30, 2022 | -9.67 Mn |
| Mar 31, 2022 | -8.62 Mn |
| Dec 31, 2021 | -11.20 Mn |
| Sep 30, 2021 | -10.54 Mn |
| Jun 30, 2021 | -11.01 Mn |